RNA Therapeutics in Cardiovascular Precision Medicine
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Since our knowledge on structure and function of messenger RNA (mRNA) has expanded from merely being an intermediate molecule between DNA and proteins to the notion that RNA is a dynamic gene regulator that can be modified and edited, RNA has become a focus of interest into developing novel therapeutic schemes. Therapeutic modulation of RNA molecules by DNA- and RNA-based therapies has broadened the scope of therapeutic targets in infectious diseases, cancer, neurodegenerative diseases and most recently in cardiovascular diseases as well. Currently, antisense oligonucleotides (ASO), small interfering RNAs (siRNAs), and microRNAs are the most widely applied therapeutic strategies to target RNA molecules and regulate gene expression and protein production. However, a number of barriers have to be overcome including instability, inadequate binding affinity and delivery to the tissues, immunogenicity, and off-target toxicity in order for these agents to evolve into efficient drugs. As cardiovascular diseases remain the leading cause of mortality worldwide, a large number of clinical trials are under development investigating the safety and efficacy of RNA therapeutics in clinical conditions such as familial hypercholesterolemia, diabetes mellitus, hypertriglyceridemia, cardiac amyloidosis, and atrial fibrillation. In this review, we summarize the clinical trials of RNA-targeting therapies in cardiovascular disease and critically discuss the advances, the outcomes, the limitations and the future directions of RNA therapeutics in precision transcriptomic medicine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association
Benjamin, E. J., Blaha, M. J., Chiuve, S. E., Cushman, M., Das, S. R., Deo, R., de Ferranti, S. D., Floyd, J., Fornage, M., Gillespie, C., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000485 · Cited by 12,591
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Long non-coding RNAs: insights into functions
Mercer, T. R., Dinger, M. E., & Mattick, J. S. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2521 · Cited by 5,654
MicroRNA therapeutics: towards a new era for the management of cancer and other diseases
Rupaimoole, R., & Slack, F. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.246 · Cited by 4,741 · cited 1×
“ASOs targeting microRNA undergo chemical modifications in order to improve their pharmacokinetic profile, binding and resistance from nuclease cleavage (Rupaimoole and Slack, 2017).”
MethodArgonaute2 is the catalytic engine of mammalian RNAi
Liu, J., Carmell, M. A., Rivas, F. V., Marsden, C. G., Thomson, J. M., Song, J.-J., Hammond, S. M., Joshua-Tor, L., & Hannon, G. J. (2004) · Science · doi:10.1126/science.1102513 · Cited by 2,796
Pegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337 · cited 1×
“This is the leading cause of blindness in people older than 50 years of age and is attributed to VEGF165-stimulated neovascularization of the choroid (Gragoudas et al., 2004).”
BackgroundNusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
Finkel, R. S., Mercuri, E., Darras, B. T., Connolly, A. M., Kuntz, N. L., Kirschner, J., Chiriboga, C. A., Saito, K., Servais, L., Tizzano, E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1702752 · Cited by 2,337 · cited 1×
“Another FDA-approved ASO is nusinersen [Spinraza, Biogen] a 18-mer phosphorothioate 2-O-methoxyethoxy antisense oligonucleotide which modulates alternative splicing of the survival motor neuron (SMN) gene and is indicated for spinal muscular atrophy (Finkel et al., 2017).”
BackgroundMonocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant.
Carr, M. W., Roth, S. J., Luther, E., Rose, S. S., & Springer, T. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.3652 · Cited by 1,198 · cited 1×
“Chemokine C-C motif-ligand 2 (CCL2) is a proinflammatory cytokine involved in the development of insulin resistance and macrophage infiltration and recent evidence supports a role of CCL2 in diabetic nephropathy (Carr et al., 1994).”
BackgroundRNA therapeutics: beyond RNA interference and antisense oligonucleotides
Kole, R., Krainer, A. R., & Altman, S. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3625 · Cited by 1,152
Overcoming cellular barriers for RNA therapeutics
Dowdy, S. F. (2017) · Nature Biotechnology · doi:10.1038/nbt.3802 · Cited by 1,139
siRNA versus miRNA as therapeutics for gene silencing
Lam, J. K. W., Chow, M. Y. T., Zhang, Y., & Leung, S. W. S. (2015) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2015.23 · Cited by 1,081 · cited 2×
“microRNAs (miRNAs) MicroRNAs are endogenous small non-coding RNAs which similarly to siRNAs regulate gene expression at a posttranscriptional level, with the exception that are capable of silencing multiple mRNAs and not one target like siRNAs (Lam et al., 2015).”
BackgroundLoss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease
The TG and HDL Working Group of the Exome Sequencing Project, N. H. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1307095 · Cited by 1,071
Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
Ray, K. K., Landmesser, U., Leiter, L. A., Kallend, D., Dufour, R., Karakas, M., Hall, T., Troquay, R. P. T., Turner, T., Visseren, F. L. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615758 · Cited by 992
Safety and efficacy of RNAi therapy for transthyretin amyloidosis
Coelho, T., Adams, D., Silva, A., Lozeron, P., Hawkins, P. N., Mant, T., Perez, J., Chiesa, J., Warrington, S., Tranter, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208760 · Cited by 971
Yin, H., Song, C.-Q., Dorkin, J. R., Zhu, L. J., Li, Y., Wu, Q., Park, A., Yang, J., Suresh, S., Bizhanova, A., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3471 · Cited by 876
A highly durable RNAi therapeutic inhibitor of PCSK9
Fitzgerald, K., White, S., Borodovsky, A., Bettencourt, B. R., Strahs, A., Clausen, V., Wijngaard, P., Horton, J. D., Taubel, J., Brooks, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609243 · Cited by 768
Viney, N. J., van Capelleveen, J. C., Geary, R. S., Xia, S., Tami, J. A., Yu, R. Z., Marcovina, S. M., Hughes, S. G., Graham, M. J., Crooke, R. M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31009-1 · Cited by 754 · cited 1×
“Concerning safety, both ASOs were well-tolerated, although two episodes of myocardial infarction were reported in the IONIS-APO(a)Rx phase 2 trial that were deemed unrelated to the study drug (Viney et al., 2016).”
BackgroundRayner, K. J., Sheedy, F. J., Esau, C. C., Hussain, F. N., Temel, R. E., Parathath, S., van Gils, J. M., Rayner, A. J., Chang, A. N., Suarez, Y., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57275 · Cited by 690 · cited 1×
“Several experimental studies are investigating the use of miRNAs as therapeutic targets in atherosclerosis, coronary artery disease and myocardial infarction and clinical trials in humans are expected to test microRNAs either as antagomiRs or microRNA mimics in cardiovascular disease (Obad et al., 2011; Rayner et al.,…”
BackgroundAdvances in the delivery of RNA therapeutics: from concept to clinical reality
Kaczmarek, J. C., Kowalski, P. S., & Anderson, D. G. (2017) · Genome Medicine · doi:10.1186/s13073-017-0450-0 · Cited by 656 · cited 1×
“Poor delivery of siRNAs due to rapid degradation by circulating nucleases or rapid renal excretion has been addressed by introducing chemical modifications including PS modifications, hydrophobic ligands and encapsulation in nano carriers, in order to increase both protection and half-life enabling systemic delivery (…”
Cellular uptake and trafficking of antisense oligonucleotides
Crooke, S. T., Wang, S., Vickers, T. A., Shen, W., & Liang, X.-H. (2017) · Nature Biotechnology · doi:10.1038/nbt.3779 · Cited by 582
Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides
Graham, M. J., Lee, R. G., Brandt, T. A., Tai, L.-J., Fu, W., Peralta, R., Yu, R., Hurh, E., Paz, E., McEvoy, B. W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701329 · Cited by 573
A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice
Yang, Y., Wang, L., Bell, P., McMenamin, D., He, Z., White, J., Yu, H., Xu, C., Morizono, H., Musunuru, K., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3469 · Cited by 556 · cited 1×
“This innovative technology has already been employed to “correct” disease contexts like Duchenne muscular dystrophy (Long et al., 2016) hereditary tyrosynemia type I (Yin et al., 2016) and lethal metabolic liver disease (Yang Y. et al., 2016) in animal models.”
MethodAntisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia
Gaudet, D., Alexander, V. J., Baker, B. F., Brisson, D., Tremblay, K., Singleton, W., Geary, R. S., Hughes, S. G., Viney, N. J., Graham, M. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1400283 · Cited by 528
Structure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing
Yin, H., Song, C.-Q., Suresh, S., Wu, Q., Walsh, S., Rhym, L. H., Mintzer, E., Bolukbasi, M. F., Zhu, L. J., Kauffman, K., et al. (2017) · Nature Biotechnology · doi:10.1038/nbt.4005 · Cited by 499 · cited 2×
“Taken together, given these advantages as well as that aptamers can be synthesized in vitro and lack immunogenicity, these agents consist an attractive alternative therapeutic strategy to monoclonal antibodies (Zhou and Rossi, 2017).”
BackgroundInactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease
Dewey, F. E., Gusarova, V., O’Dushlaine, C., Gottesman, O., Trejos, J., Hunt, C., Van Hout, C. V., Habegger, L., Buckler, D., Lai, K.-M. V., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1510926 · Cited by 497 · cited 1×
“Several lines of evidence support a beneficial metabolic profile in patients with loss-of-function genetic variants in the gene encoding ANGPTL3 and ANGPTL4 expressed as low levels of plasma LDL cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides, and reduced insulin resistance (Robciuc et al., 2013…”
BackgroundTsimikas, S., Viney, N. J., Hughes, S. G., Singleton, W., Graham, M. J., Baker, B. F., Burkey, J. L., Yang, Q., Marcovina, S. M., Geary, R. S., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)61252-1 · Cited by 460
Oxidized Phospholipids, Lipoprotein(a), and Progression of Calcific Aortic Valve Stenosis
Capoulade, R., Chan, K. L., Yeang, C., Mathieu, P., Bossé, Y., Dumesnil, J. G., Tam, J. W., Teo, K. K., Mahmut, A., Yang, X., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.07.020 · Cited by 417
Graham, M. J., Lee, R. G., Bell, T. A., Fu, W., Mullick, A. E., Alexander, V. J., Singleton, W., Viney, N., Geary, R., Su, J., et al. (2013) · Circulation Research · doi:10.1161/circresaha.111.300367 · Cited by 377 · cited 1×
“In a phase 1 study, healthy volunteers received either placebo (n = 8) or volanesorsen (ISIS 304801) (n = 25) and presented a deep dose-dependent reduction up to ∼90% and up to ∼80% of APOC-III and triglyceride levels, respectively 4 weeks post-treatment (Graham et al., 2013; Table 1).”
BackgroundSuhr, O. B., Coelho, T., Buades, J., Pouget, J., Conceicao, I., Berk, J., Schmidt, H., Waddington-Cruz, M., Campistol, J. M., Bettencourt, B. R., et al. (2015) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-015-0326-6 · Cited by 321
Antisense oligonucleotide therapy for spinocerebellar ataxia type 2
Scoles, D. R., Meera, P., Schneider, M. D., Paul, S., Dansithong, W., Figueroa, K. P., Hung, G., Rigo, F., Bennett, C. F., Otis, T. S., et al. (2017) · Nature · doi:10.1038/nature22044 · Cited by 319
Bennet, A. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.6.598 · Cited by 281 · cited 1×
“85) between the upper and lower thirds of baseline Lp(a) levels after adjustment for traditional cardiovascular risk factors (Bennet et al., 2008).”
BackgroundThomas, G. S., Cromwell, W. C., Ali, S., Chin, W., Flaim, J. D., & Davidson, M. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.07.081 · Cited by 245
Karatasakis, A., Danek, B. A., Karacsonyi, J., Rangan, B. V., Roesle, M. K., Knickelbine, T., Miedema, M. D., Khalili, H., Ahmad, Z., Abdullah, S., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.006910 · Cited by 215
Digenio, A., Dunbar, R. L., Alexander, V. J., Hompesch, M., Morrow, L., Lee, R. G., Graham, M. J., Hughes, S. G., Yu, R., Singleton, W., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0126 · Cited by 170
Yang, X., Lee, S.-R., Choi, Y.-S., Alexander, V. J., Digenio, A., Yang, Q., Miller, Y. I., Witztum, J. L., & Tsimikas, S. (2016) · Journal of Lipid Research · doi:10.1194/jlr.m066399 · Cited by 103
Apolipoprotein C-III: Going Back to the Future for a Lipid Drug Target
Huff, M. W., & Hegele, R. A. (2013) · Circulation Research · doi:10.1161/circresaha.113.301464 · Cited by 70 · cited 1×
“APOC-III exerts its atherogenic action by attenuating lipolysis of triglyceride-rich lipoproteins through lipoprotein lipase (LPL) inhibition that results in increased circulating levels of very low density lipoproteins and chylomicrons (Huff and Hegele, 2013).”
Background
Cited by
RNA-Targeted Therapies and High-Throughput Screening Methods
Zhu, S., Rooney, S., & Michlewski, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082996 · Cited by 41
RNA-binding proteins in vascular inflammation and atherosclerosis
Sachse, M., Tual-Chalot, S., Ciliberti, G., Amponsah-Offeh, M., Stamatelopoulos, K., Gatsiou, A., & Stellos, K. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.01.008 · Cited by 29
Self-citationHu, J., Wang, J., Zhang, H., Jiang, Y., Deng, L., Long, E., & Liu, S. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1758366 · Cited by 3
“The antisense strand within RISC is protected from degradation, and chemical modifications further enhance stability (36, 37).”
Metadata
- Authors
- Laina, A., Gatsiou, A., Georgiopoulos, G., Stamatelopoulos, K., & Stellos, K.
- Venue
- Frontiers in Physiology
- Publisher
- Frontiers Media SA
- Published
- 2018-07-25
- Volume
- 9
- Pages
- 953-953
- ISSN
- 1664-042X (ISSN-L)
- OpenAlex
- W2810036884
- Cited by
- 88
- References
- 36
- FWCI
- 3.30
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.